The stock of Precigen Inc (NASDAQ: PGEN) has decreased by 0.00 when compared to last closing price of 1.41.Despite this, the company has seen a gain of 0.71% in its stock price over the last five trading days. Seeking Alpha reported 2024-01-19 that FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis.
Is It Worth Investing in Precigen Inc (NASDAQ: PGEN) Right Now?
The 36-month beta value for PGEN is at 1.77. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PGEN is 123.71M, and currently, shorts hold a 13.66% of that float. The average trading volume for PGEN on April 11, 2024 was 1.05M shares.
PGEN’s Market Performance
The stock of Precigen Inc (PGEN) has seen a 0.71% increase in the past week, with a -9.32% drop in the past month, and a 0.71% gain in the past quarter. The volatility ratio for the week is 4.91%, and the volatility levels for the past 30 days are at 5.62% for PGEN. The simple moving average for the past 20 days is -1.35% for PGEN’s stock, with a 5.58% simple moving average for the past 200 days.
Analysts’ Opinion of PGEN
Cantor Fitzgerald gave a rating of “Overweight” to PGEN, setting the target price at $7 in the report published on November 18th of the previous year.
PGEN Trading at -3.59% from the 50-Day Moving Average
After a stumble in the market that brought PGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.00% of loss for the given period.
Volatility was left at 5.62%, however, over the last 30 days, the volatility rate increased by 4.91%, as shares sank -6.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.73% lower at present.
During the last 5 trading sessions, PGEN rose by +0.71%, which changed the moving average for the period of 200-days by +24.78% in comparison to the 20-day moving average, which settled at $1.4245. In addition, Precigen Inc saw 5.22% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PGEN starting from KIRK RANDAL J, who purchase 96,686 shares at the price of $1.41 back on Dec 28 ’23. After this action, KIRK RANDAL J now owns 1,096,686 shares of Precigen Inc, valued at $136,327 using the latest closing price.
KINDLER JEFFREY B, the Director of Precigen Inc, sale 96,686 shares at $1.41 during a trade that took place back on Dec 28 ’23, which means that KINDLER JEFFREY B is holding 238,275 shares at $136,327 based on the most recent closing price.
Stock Fundamentals for PGEN
Current profitability levels for the company are sitting at:
- -3.51 for the present operating margin
- 0.66 for the gross margin
The net margin for Precigen Inc stands at 0.52. The total capital return value is set at -0.59. Equity return is now at value -78.37, with -49.78 for asset returns.
Based on Precigen Inc (PGEN), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -9.43. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -161.6.
Currently, EBITDA for the company is -82.25 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 16.25. The receivables turnover for the company is 13.69for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.99.
Conclusion
In conclusion, Precigen Inc (PGEN) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
